• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

STAAR Surgical markets phakic IOL in Canada

Article

The Canadian Therapeutic Products Directorate said it granted approval for STAAR Surgical Co. to market its STAAR Visian Toric lens (TICL) in Canada.

The Canadian Therapeutic Products Directorate said it granted approval for STAAR Surgical Co. to market its STAAR Visian Toric lens (TICL) in Canada.

The posterior chamber phakic IOL is the first to be approved to correct both myopia and astigmatism in a single procedure, the company said in a prepared statement.

Used as part of the customized refractive procedure, the IOL offers a solution that corrects these vision deficiencies without the removal or destruction of corneal tissue, according to the company.

Related Videos
EyeCon 2024: Peter J. McDonnell, MD, marvels on mentoring, modern technology, and ophthalmology’s future
Lorraine Provencher, MD, presenting slides
Katherine Talcott, MD, presenting slides
Katherine Talcott, MD, presenting slides
© 2024 MJH Life Sciences

All rights reserved.